Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.96
- Piotroski Score 2.00
- Grade Buy
- Symbol (OBIO)
- Company Orchestra BioMed Holdings, Inc.
- Price $5.44
- Changes Percentage (3.03%)
- Change $0.16
- Day Low $5.23
- Day High $5.64
- Year High $11.69
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.46
- Trailing P/E Ratio -5.47
- Forward P/E Ratio -5.47
- P/E Growth -5.47
- Net Income $-49,120,000
Income Statement
Quarterly
Annual
Latest News of OBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
FibroBiologics and Charles River link for chronic disease therapies manufacture
FibroBiologics partners with Charles River Laboratories to manufacture cell-based therapies for chronic diseases, including CYWC628 for diabetic foot ulcers. This collaboration aims to advance regener...
By Yahoo! Finance | 1 month ago -
Pope Francis Makes History with New Autobiography Hope, Originally Meant to Be Published After His Death
Pope Francis is releasing his autobiography "Hope," sharing his journey of hope and faith. The book, written with Carlo Musso, includes personal stories and unpublished material. Published ahead of th...
By PEOPLE.com | 1 month ago -
Italy's Probios launches VC initiative to back healthy food start-ups
Italian organic and gluten-free food manufacturer Probios is launching Probios Ventures to support startups in health food and nutrition sectors. The venture aims to provide capital, mentorship, and a...
By Yahoo! Finance | 1 month ago
